Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Clin Pharmacol Ther. 2015 Nov 20;99(2):172–185. doi: 10.1002/cpt.280

Table 3.

Groups, organizations and stakeholders represented by the Workgroup members

Pharmacogenetics community:

  • Pharmacogenomics Knowledge Base (PharmGKB)

  • Pharmacogenomics Research Network (PGRN)

  • Clinical Pharmacogenetics Implementation Consortium (CPIC)*

  • European Pharmacogenetic Implementation Consortium (Eu-PIC)

  • Ubiquitous Pharmacogenomics (U-PGx)

  • European Society for Pharmacogenomics and Personalized Therapy (ESPT)

  • International Federation for Clinical Chemistry (IFCC) Task Force –Pharmacogenetics

  • ClinGen PGx Working Group

Regulatory/Governmental Agencies:

  • Food and Drug Administration (FDA)**

  • European Medicine Agency (EMA) PGx Working Group

  • College of American Pathologists (CAP)

  • Centers for Disease Control and Prevention (CDC)

  • National Institutes of Health (NIH)

Genetic Nomenclature Committees:

  • HUGO Gene Nomenclature Committee (HGNC)

  • Human Genome Variation Society (HGVS)

Gene Variant Databases:

  • National Center for Biotechnology Information (NCBI)

  • ClinVar

  • Genetic Testing Registry (GTR)

  • RefSeqGene

  • MedGen

  • European Bioinformatics Institute (EBI)

  • Locus Reference Genomic (LRG)

  • Leiden Open Variation Database (LOVD)

PGx Gene Specific Nomenclature Committees and Databases:

  • Human Cytochrome P450 (CYP) Allele Nomenclature Database

  • UDP-Glucuronosyltransferase (UGT) Alleles Nomenclature Page

  • Thiopurine methyltransferase (TPMT) Nomenclature Committee

  • Arylamine N-acetyltransferase (NAT) Gene Nomenclature Committee

Professional societies and Standards Development Organizations:

  • International Federation for Clinical Chemistry (IFCC)

  • Association for Molecular Pathology (AMP)

  • HL7 Clinical Genomics Working Group

PGx test developers
Clinical and research laboratories
*

Caudle, K.E. et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Current drug metabolism 15, 209-17 (2014)

**

FDA supports efforts towards PGx nomenclature standardization but the use of standardized nomenclature is not currently a regulatory requirement for clearance or approval of in vitro diagnostic tests.